Literature DB >> 11551375

Medical management of primary hyperaldosteronism.

E L Bravo1.   

Abstract

Most forms of primary aldosteronism are surgically correctable. However, when surgery is not appropriate, medical management is just as effective in correcting the pathophysiologic abnormalities due to aldosterone excess. A prerequisite for the rational medical management of primary aldosteronism is an understanding of the mechanisms that sustain hypertension. Primary aldosteronism can be associated with severe and resistant hypertension, and persistent hypervolemia is the primary reason for resistance to therapy. Patients with overriding comorbidities or strong preferences have been medically treated over the intermediate term of 5 to 7 years without evidence of escape or evidence of malignant transformation of adrenal adenomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11551375     DOI: 10.1007/s11906-001-0058-y

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  9 in total

1.  Hemodynamic characteristics of primary aldosteronism.

Authors:  R C Tarazi; M M Ibrahim; E L Bravo; H P Dustan
Journal:  N Engl J Med       Date:  1973-12-20       Impact factor: 91.245

2.  Spironolactone as a nonspecific treatment for primary aldosteronism.

Authors:  E L Bravo; H P Dustan; R C Tarazi
Journal:  Circulation       Date:  1973-09       Impact factor: 29.690

3.  Dependence of arterial pressure on intravascular volume in treated hypertensive patients.

Authors:  H P Dustan; R C Tarazi; E L Bravo
Journal:  N Engl J Med       Date:  1972-04-20       Impact factor: 91.245

4.  Clinical implications of primary aldosteronism with resistant hypertension.

Authors:  E L Bravo; F M Fouad-Tarazi; R C Tarazi; M Pohl; R W Gifford; D G Vidt
Journal:  Hypertension       Date:  1988-02       Impact factor: 10.190

5.  Hemodynamic and reflex responses to acute and chronic antihypertensive therapy with the calcium entry blocker nifedipine.

Authors:  W Kiowski; O Bertel; P Erne; P Bolli; U L Hulthén; R Ritz; F R Bühler
Journal:  Hypertension       Date:  1983 Mar-Apr       Impact factor: 10.190

6.  The changing clinical spectrum of primary aldosteronism.

Authors:  E L Bravo; R C Tarazi; H P Dustan; F M Fouad; S C Textor; R W Gifford; D G Vidt
Journal:  Am J Med       Date:  1983-04       Impact factor: 4.965

7.  Selective hypoaldosteronism despite prolonged pre- and postoperative hyperreninemia in primary aldosteronism.

Authors:  E L Bravo; H P Dustan; R C Tarazi
Journal:  J Clin Endocrinol Metab       Date:  1975-09       Impact factor: 5.958

8.  Medical management of aldosterone-producing adenomas.

Authors:  R P Ghose; P M Hall; E L Bravo
Journal:  Ann Intern Med       Date:  1999-07-20       Impact factor: 25.391

Review 9.  Primary aldosteronism. Issues in diagnosis and management.

Authors:  E L Bravo
Journal:  Endocrinol Metab Clin North Am       Date:  1994-06       Impact factor: 4.741

  9 in total
  4 in total

1.  Primary aldosteronism associated with subclinical Cushing syndrome.

Authors:  K Fujimoto; S Honjo; H Tatsuoka; Y Hamamoto; Y Kawasaki; A Matsuoka; H Ikeda; Y Wada; H Sasano; H Koshiyama
Journal:  J Endocrinol Invest       Date:  2013-02-04       Impact factor: 4.256

Review 2.  Adrenocortical hypertension.

Authors:  Angelo Capricchione; Nathaniel Winer; James R Sowers
Journal:  Curr Hypertens Rep       Date:  2004-06       Impact factor: 5.369

Review 3.  Prediction of successful outcome in patients with primary aldosteronism.

Authors:  Tracy-Ann Moo; Rasa Zarnegar; Quan-Yang Duh
Journal:  Curr Treat Options Oncol       Date:  2007-08

4.  Adrenocortical hypertension.

Authors:  Angelo Capricchione; Nathaniel Winer; James R Sowers
Journal:  Curr Urol Rep       Date:  2006-01       Impact factor: 2.862

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.